APA (7th ed.) Citation

Shimazu, Y., Kanda, J., Kaneko, H., Imada, K., Yamamura, R., Kosugi, S., . . . Tanaka, Y. (2022). Monocyte or white blood cell counts and β2 microglobulin predict the durable efficacy of daratumumab with lenalidomide. Therapeutic advances in hematology, 13, 1. https://doi.org/10.1177/20406207221142487

Chicago Style (17th ed.) Citation

Shimazu, Yutaka, et al. "Monocyte or White Blood Cell Counts and β2 Microglobulin Predict the Durable Efficacy of Daratumumab with Lenalidomide." Therapeutic Advances in Hematology 13 (2022): 1. https://doi.org/10.1177/20406207221142487.

MLA (9th ed.) Citation

Shimazu, Yutaka, et al. "Monocyte or White Blood Cell Counts and β2 Microglobulin Predict the Durable Efficacy of Daratumumab with Lenalidomide." Therapeutic Advances in Hematology, vol. 13, 2022, p. 1, https://doi.org/10.1177/20406207221142487.